Nov 22 (Reuters) - The U.S. health regulator on Tuesday approved Australian drugmaker CSL Ltd (CSL) and partner Uniqure NV's QURE.O gene therapy for hemophilia B, potentially offering a long-term solution for patients with the blood clotting disorder.
The approval from the Food and Drug Administration makes the treatment, which will be branded Hemgenix, the first gene therapy for the rare inherited disorder that is usually treated by regular injections of clotting protein factor IX.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$267.92 |
Change
-1.640(0.61%) |
Mkt cap ! $129.7B | |||
| Open | High | Low | Value | Volume |
| $269.56 | $270.42 | $267.15 | $252.9M | 957.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 879 | $267.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $268.98 | 120 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |